Status:
COMPLETED
The Effect of Per Oral Immunotherapy in Severe IgE Mediated Egg, Milk, and Nut Allergy in Adults
Lead Sponsor:
Helsinki University Central Hospital
Conditions:
Food Allergy
Eligibility:
All Genders
18-50 years
Phase:
NA
Brief Summary
In Finland, the estimated prevalence of physician-diagnosed food allergy in 1-4 year old children is 9%, and the most common allergen is milk. The overall food allergy has been reported to be 3.7%. He...
Detailed Description
Up to 100 subjects are studied. All subjects are adults having no other severe chronic diseases. The subjects belong to four different groups: 1. 30 18-50 year olds who start per oral immunotherapy t...
Eligibility Criteria
Inclusion
- severe IgE-mediated milk allergy or
- severe IgE-mediated egg allergy or
- severe IgE-mediated nut allergy or
- 18-50 years
Exclusion
- instable cerebrovascular or heart disease
- active autoimmune disease or cancer
- use of betablocker agents
- poorly controlled asthma
- FEV1 \< 70% of the predicted
Key Trial Info
Start Date :
January 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2017
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT01822353
Start Date
January 1 2013
End Date
November 1 2017
Last Update
February 11 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Helsinki University Central Hospital
Helsinki, Finland, 00029